Emcure Pharmaceuticals Ltd Financial Statement
*All values are in Rs. Cr
| Particulars | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|
| Revenue | 1,159.56 | 1,002.80 | 936.70 |
| Operating Expense | 952.47 | 855.11 | 805.55 |
| Net Profit | 86.92 | 40.45 | 28.98 |
| Net Profit Margin | 7.50 | 4.03 | 3.09 |
| Earning Per Share | 4.62 | 2.23 | 1.60 |
| EBIDTA | 204.34 | 146.01 | 131.07 |
| Effective Tax Rate | 14.33 | 8.74 | 4.89 |
| Particulars | Sep 2024 |
|---|---|
| Revenue | 1159.56 |
| Operating Expense | 952.47 |
| Net Profit | 86.92 |
| Net Profit Margin | 7.50 |
| Earning Per Share | 4.62 |
| EBIDTA | 204.34 |
| Effective Tax Rate | 14.33 |
Invest in Emcure Pharmaceuticals Ltd
₹0 Brokerage*
Open Demat Account
*By signing up you agree to our Terms and Conditions
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|
| Total Revenue Annual | 3,107.09 | 3,387.24 | 3,107.41 |
| Operating Expenses Annual | 2,668.59 | 2,592.57 | 2,367.40 |
| Operating Profit Annual | 557.70 | 927.35 | 830.39 |
| Interest Annual | 166.83 | 145.14 | 118.28 |
| Depreciation | 156.51 | 142.73 | 133.50 |
| Net Profit Annual | 160.06 | 446.81 | 422.10 |
| Tax Annual | 52.28 | 169.61 | 137.42 |
| Particulars | Mar 2023 |
|---|---|
| Total Revenue Annual | 3,107.09 |
| Operating Expenses Annual | 2,668.59 |
| Operating Profit Annual | 557.70 |
| Interest Annual | 166.83 |
| Depreciation | 156.51 |
| Net Profit Annual | 160.06 |
| Tax Annual | 52.28 |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|
| Cash Flow at the Beginning | -393.35 | -84.29 | -54.35 |
| Cash Flow from Operations | 505.37 | 427.71 | 774.87 |
| Cash Flow from Investing | -270.56 | -393.81 | -835.78 |
| Cash Flow from Financing | -54.52 | -342.96 | 30.97 |
| Cash Flow at the End | -213.05 | -393.35 | -84.29 |
| Particulars | Mar 2023 |
|---|---|
| Cash Flow at the Beginning | -393.35 |
| Cash Flow from Operations | 505.37 |
| Cash Flow from Investing | -270.56 |
| Cash Flow from Financing | -54.52 |
| Cash Flow at the End | -213.05 |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|
| PBDIT Margin (%) | 17.95 | 27.38 | 26.72 |
| PBIT Margin (%) | 12.20 | 22.48 | 21.76 |
| PBT Margin (%) | 12.13 | 22.33 | 21.58 |
| Net PROFIT Margin (%) | 5.15 | 13.19 | 13.53 |
| Return On Networth / Equity (%) | 9.01 | 22.26 | 19.95 |
| Return On Networth /Employed (%) | 10.71 | 20.50 | 18.77 |
| Return On Assets (%) | 4.53 | 12.00 | 11.64 |
| Total Debt / Equity (X) | 0.91 | 0.79 | 0.68 |
| Asset Turnover Ratio (%) | 0.88 | 0.91 | 0.86 |
| Particulars | Mar 2023 |
|---|---|
| PBDIT Margin (%) | 17.95 |
| PBIT Margin (%) | 12.20 |
| PBT Margin (%) | 12.13 |
| Net PROFIT Margin (%) | 5.15 |
| Return On Networth / Equity (%) | 9.01 |
| Return On Networth /Employed (%) | 10.71 |
| Return On Assets (%) | 4.53 |
| Total Debt / Equity (X) | 0.91 |
| Asset Turnover Ratio (%) | 0.88 |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|
| Fixed Assets Annual | 1,268.20 | 1,151.48 | 1,147.24 |
| Total Current Assets Annual | 2,159.41 | 2,141.63 | 2,215.46 |
| Non Current Assets Annual | 2,456.44 | 2,181.56 | 2,647.74 |
| Total Shareholders Funds Annual | 1,841.87 | 1,712.53 | 2,301.77 |
| Total Assets Annual | 4,615.85 | 4,323.18 | 4,863.20 |
| Particulars | Mar 2023 |
|---|---|
| Fixed Assets Annual | 1,268.20 |
| Total Current Assets Annual | 2,159.41 |
| Non Current Assets Annual | 2,456.44 |
| Total Shareholders Funds Annual | 1,841.87 |
| Total Assets Annual | 4,615.85 |
EPS (INR)
Expected
10.29
Reported
10.23
Surprise
-0.58%
Jun 2024
EPS beaten by -0.58%
Mar 2024
EPS beaten by 0.00%
Dec 2023
EPS beaten by 0.00%
